Bausch Health Companies (BHC) Non-Current Debt (2009 - 2026)
Bausch Health Companies (BHC) posted Non-Current Debt of $20.7 billion for Q2 2026, little changed sequentially from $20.8 billion in Q1 2026, and down 4.59% YoY from $21.7 billion in Q2 2025.
Bausch Health Companies (BHC) Non-Current Debt (2009 - 2026) Analysis & Trends
Bausch Health Companies has reported Non-Current Debt for 18 years, with the latest figure at $20.7 billion in Q2 2026.
- Quarterly Non-Current Debt fell 4.59% year-over-year to $20.7 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $20.7 billion (down 4.59% YoY) and the FY2025 annual result came in at $20.8 billion, down 3.7% from the prior year.
- Non-Current Debt held at $20.7 billion in Q2 2026 per BHC's latest filing, from $20.8 billion in the prior quarter.
- Over five years, Non-Current Debt peaked at $23.2 billion in Q1 2022 and troughed at $20.6 billion in Q2 2023.
- A 5-year average of $21.5 billion and a median of $21.5 billion in 2024 frame the typical range for Non-Current Debt.
- The widest YoY moves for Non-Current Debt: up 7.81% in 2023, down 10.86% in 2023.
- Over 5 years, Non-Current Debt stood at $20.8 billion in 2022, then rose by 7.81% to $22.4 billion in 2023, then slipped by 3.45% to $21.6 billion in 2024, then declined by 3.7% to $20.8 billion in 2025, then retreated by 0.37% to $20.7 billion in 2026.
- According to Business Quant data, Non-Current Debt over the past three periods registered $20.7 billion, $20.8 billion, and $20.8 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 130.00 Mn |
| 10 | Bausch Health Companies | 2.42 Bn | 586.38 Mn | 2.10 Bn | 20.74 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.74 Bn |
| Mar 31, 2026 | 20.76 Bn |
| Dec 31, 2025 | 20.82 Bn |
| Sep 30, 2025 | 20.46 Bn |
| Jun 30, 2025 | 21.74 Bn |
| Mar 31, 2025 | 21.51 Bn |
| Dec 31, 2024 | 18.94 Bn |
| Sep 30, 2024 | 21.51 Bn |
| Jun 30, 2024 | 21.21 Bn |
| Mar 31, 2024 | 21.54 Bn |
| Dec 31, 2023 | 21.94 Bn |
| Sep 30, 2023 | 22.43 Bn |
| Jun 30, 2023 | 20.11 Bn |
| Mar 31, 2023 | 20.65 Bn |
| Dec 31, 2022 | 20.77 Bn |
| Sep 30, 2022 | 20.80 Bn |
| Jun 30, 2022 | 21.81 Bn |
| Mar 31, 2022 | 23.17 Bn |
| Dec 31, 2021 | 22.65 Bn |
| Sep 30, 2021 | 22.36 Bn |